Deep brain stimulation benefits UAE patients affected by Parkinson's disease

Cleveland Clinic Abu Dhabi Provides Deep Brain Stimulation as Innovative New Treatment

Deep brain stimulation benefits UAE patients affected by Parkinson's disease

Abu Dhabi, United Arab Emirates: Cleveland Clinic Abu Dhabi, part of Mubadala’s healthcare network, has introduced deep brain stimulation to the UAE, providing Parkinson’s disease patients with a treatment that can help them manage the symptoms and reduce their dependence on medication.

James, an American expatriate in his 50s, was first diagnosed with Parkinson’s disease at the age of 42, significantly earlier than the global average of 56 years old. Unlike the traditional image of Parkinson’s disease, he did not experience tremors. Instead, James felt stiff, slow, and had difficulty walking. Following his diagnosis, he began taking medication to manage his symptoms.

By the time he was 54, the severity of his symptoms increased, and the medication was losing its effectiveness, forcing him to increase the amount he took every day.

“I would begin to seize up and find myself unable to move while I waited for my medication to take effect. I remember it got to the point where I stopped eating so that food in my stomach wouldn’t interfere with the absorption. I was in a really tough situation and knew I needed to do something urgently,” says James.

Last year, James visited Cleveland Clinic Abu Dhabi where he was informed the hospital had begun evaluating patients for deep brain stimulation, a surgical procedure that uses electrodes implanted in the brain to control Parkinson’s disease symptoms. Following a comprehensive evaluation by a multidisciplinary panel, including a speech and physical therapist, psychiatrist, psychologist and neurosurgeon, the care team considered James a good candidate for the surgery.

“The goal of Parkinson’s disease treatment is to improve a patient’s quality of life, helping them to keep moving and live an active life. As it is a progressive condition, the longer a patient has the disease the worse their symptoms become. Deep brain stimulation not only allows us to control symptoms throughout the day, it reduces a person’s reliance on medication,” says Dr. Shivam Om Mittal, Consultant neurologist, Section Head for Parkinson’s disease and movement disorders at Cleveland Clinic Abu Dhabi.

Following his Deep Brain Stimulation surgery, his care team prepared to begin the complex process of tuning the electrodes implanted in his brain to block the rogue signals causing his symptoms.  This required several visits to the movement disorders clinic at Cleveland Clinic Abu Dhabi for fine tuning and programming of the DBS device. Once properly configured, James was able to significantly reduce his medication and has returned to work.

“It has been a transformation. I’m able to move a lot better, I go for walks now and I am eating normally. I’m back at work and really feel like I have my life back,” says James.

Globally, Parkinson’s disease affects around 7 million people. However, doctors have warned that the number of cases will double by 2040 as the world’s population ages.

“James is one of a small percentage of patients around the world with early onset Parkinson’s disease, although the numbers are growing. These are the patients who will see the greatest benefit from this surgery as their symptoms will have a lot more time to progress,” concludes Dr. Mittal.

For more information or to book an appointment at Cleveland Clinic Abu Dhabi, call 800 8 CCAD (2223) visit or download the Cleveland Clinic Abu Dhabi app.

About Cleveland Clinic Abu Dhabi

Cleveland Clinic Abu Dhabi, part of Mubadala’s network of world-class healthcare providers, is a multispecialty hospital on Al Maryah Island in Abu Dhabi, UAE. Cleveland Clinic Abu Dhabi is a unique and unparalleled extension of US-based Cleveland Clinic’s model of care, specifically designed to address a range of complex and critical care requirements unique to the Abu Dhabi population.

Cleveland Clinic Abu Dhabi has the following Institutes: Heart & Vascular, Neurological, Digestive Disease, Eye, Respiratory, Critical Care, Surgical Subspecialties, Medical Subspecialties, Emergency Medicine, Anesthesiology, Pathology & Laboratory Medicine, Imaging, Quality & Patient Safety, and Clinical & Nursing. In all, more than 40 medical and surgical specialties are represented at Cleveland Clinic Abu Dhabi.

The facilities at Cleveland Clinic Abu Dhabi combine state-of-the-art amenities and world-class service standards. The hospital is a 394 (expandable to 490) bed facility, with five clinical floors, three diagnostic and treatment levels, and 13 floors of critical and acute inpatient units. It is a physician-led medical facility served by North American/European Board Certified (or equivalent) physicians. Cleveland Clinic Abu Dhabi provides patients in the region direct access to the world’s best healthcare providers and Cleveland Clinic’s unique model of care, reducing their need to travel abroad for treatment.

Cleveland Clinic Abu Dhabi – Al Ain began offering select medical services in December 2017. The facility is located on the Tawam Hospital Campus in Al Ain.

Visit us at 

Mubadala Investment Company

Mubadala Investment Company is a sovereign investor managing a global portfolio, aimed at generating sustainable financial returns for the Government of Abu Dhabi.

Mubadala’s $232 billion (AED 853 billion) portfolio spans six continents with interests in multiple sectors and asset classes. We leverage our deep sectoral expertise and long-standing partnerships to actively source deals. In the UAE, we are driving sustainable growth by optimizing scale and efficiency, supporting the continued diversification and global integration of the local economy while growing our shareholder value. 

Headquartered in Abu Dhabi, Mubadala has offices in London, Rio de Janeiro, Moscow, New York, San Francisco and Beijing.

For more information about Mubadala, please visit: 

Send us your press releases to

© Press Release 2020

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.

More From Press Releases